![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Purpose
Non-infectious chronic anterior uveitis (CAU) remains a therapeutic challenge. The purpose of this study was to analyze the effectiveness and safety of weekly dosing of adalimumab in children with non-infectious refractory CAU. Methods: Demographic and clinical data of children followed by non-infectious CAU treated with adalimumab were retrospectively reviewed.
Results
Of the 42 children with CAU, 27/42 (64.3%) were treated with adalimumab. Escalation to weekly dosing of adalimumab was necessary for 11/27 children (40.7%). After 3 and 6 months, 7/11 children (63.6%) met the composite endpoint of inflammation control improvement. Children requiring weekly adalimumab had initially more severe uveitis: anterior chamber cells (p = 0.02), aqueous flare (p = 0.02), and presence of macular edema (p = 0.007). No children had serious systemic side effects.
Conclusion
Weekly adalimumab in children with refractory CAU appears to be an effective and safe treatment for inflammation control and corticosteroid sparing, and an alternative before biologic switching. Controlled studies are needed.
Acknowledgments
The authors are grateful to Nikki Sabourin-Gibbs, CHU Rouen, for her help in editing the manuscript. The authors would like to thank Sophie Mazet, CHU Rouen, for her help in organizing the dedicated consultation.
Disclosure statement
JG is consultant for Sanofi and Thea. JH, MM, SR, SDM, MGL declare no competing interests. All authors attest that they meet the current ICMJE criteria for authorship.
Ethics statement
This study has been approved by the Ethics Committee for Research on Existing Data of Rouen University Hospital E2022-42. A waiver of informed consent was obtained as the study was a retrospective chart review.